Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Cytori Therapeutics
Information provided by (Responsible Party):
Cytori Therapeutics Identifier:
First received: March 14, 2012
Last updated: January 30, 2014
Last verified: January 2014

This is a prospective, randomized, placebo-controlled, double blind safety and feasibility clinical trial.

Condition Intervention Phase
Myocardial Ischemia
Device: ADRCs processed by the Celution System
Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.

Resource links provided by NLM:

Further study details as provided by Cytori Therapeutics:

Primary Outcome Measures:
  • Treatment emergent serious adverse events (SAEs), major adverse cardiac events (MACE), arrhythmia assessment, change in cardiac function and symptoms, and resource utilization [ Time Frame: 6 and 12 Months ] [ Designated as safety issue: Yes ]

    Safety endpoints include:

    1. Treatment emergent SAEs
    2. Arrhythmia assessment via Holter monitoring
    3. MACE defined as cardiac death and hospitalization for heart failure

    Feasibility endpoints include:

    1. Change in mVO2 at 6 months
    2. Change in LVESV/LVEDV at 6 months
    3. Change in ejection fraction at 6 months
    4. Change in perfusion defect at 6 months
    5. Resource utilization
    6. Change in heart failure symptoms, angina, and quality of life through 12 months

Estimated Enrollment: 45
Study Start Date: June 2012
Estimated Study Completion Date: May 2019
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ADRCs processed by the Celution System
400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
Device: ADRCs processed by the Celution System
Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
Other Names:
  • ADRCs
  • Intramyocardial injections
Placebo Comparator: Lactated Ringers and Subject's blood
Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
Other Name: Placebo

Detailed Description:

To assess the safety and feasibility of Adipose-Derived Regenerative Cells (ADRCs) delivered via an intramyocardial route in the treatment of chronic ischemic heart disease in patients who are not eligible for percutaneous or surgical revascularization.


Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Males or females 20-80 years of age
  2. Significant multi-vessel coronary artery disease not amenable to percutaneous or surgical revascularization in the target area
  3. CCS Angina Functional Class II-IV and/or NYHA Stages of Heart Failure Class II or III
  4. On maximal medical therapy for anginal symptoms and or heart failure symptoms
  5. Hemodynamic stability (Systolic Blood Pressure ≥ 90 mm/Hg, Heart Rate < 110; Pulse-Oxygen > 95)
  6. Ejection fraction ≤ 45
  7. Left ventricular wall thickness ≥ 8 mm at the target site for cell injection, confirmed by 2D contrast echo within 4 weeks prior to enrollment, free of thrombus

Key Exclusion Criteria:

  1. Atrial fibrillation or flutter without a pace maker that guarantees a stable heart rate
  2. Unstable angina
  3. LV thrombus, as documented by echocardiography
  4. Planned staged treatment of CAD or other intervention on the heart
  5. Platelet count < 100,000/mm3
  6. WBC < 2,000/mm3
  7. TIA or stroke within 90 days prior to randomization
  8. ICD shock within 30 days of randomization
  9. Any condition requiring immunosuppressive medication
  10. A high-risk acute coronary syndrome (ACS) or a myocardial infarction within 60 days prior to randomization
  11. Revascularization within 60 days prior to randomization
  12. Inability to walk on a treadmill except for class IV angina patients who will be evaluated separately
  13. Hepatic dysfunction, as defined as aspartate aminotransferase (AST) and /or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal range (x ULN) prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01556022

Contact: Eve Taylor, PhD 858-458-0900
Contact: Rhiannon Dabkowski, BS 858-458-0900

United States, Alabama
Cardiology, P.C. Recruiting
Birmingham, Alabama, United States, 35211
Contact: Susan DeRamus, RN, CCRC    205-949-5275   
Principal Investigator: Farrell O. Mendelsohn, MD         
United States, California
Scripps Clinic - Torrey Pines, Scripps Green Hospital Recruiting
La Jolla, California, United States, 92037
Contact: Heather Catchpole, MS, CCRC    858-554-5258   
Principal Investigator: Richard A. Schatz, MD, FACC         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Dana Leach, DNP, ARNP-C    352-273-8930   
Principal Investigator: Carl J. Pepine, MD         
Florida Hospital-Pepin Heart Institute Recruiting
Tampa, Florida, United States, 33613
Contact: Brian K. Nordgren, DrHSc, MPH, PA-C    813 615-7527    Brian.Nordgren@AHSS.ORG   
Principal Investigator: Charles R. Lambert, MD         
United States, Minnesota
Minneapolis Heart Institute Foundation Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Rachel Olson, RN, MS, CCRC    612-863-3818   
Principal Investigator: Timothy Henry, MD         
United States, North Carolina
Duke University Hospital Recruiting
Durham, North Carolina, United States, 27705
Contact: James Gibbs, RN    919-681-4684   
Contact: Krista Camuglia, BSN    (919) 681-6949   
Principal Investigator: Thomas Povsic, MD         
United States, Texas
Texas Heart Institute Recruiting
Houston, Texas, United States, 77030
Contact: Deirdre Smith, RN, CCRC    832-355-9801   
Contact: Jennifer Chambers, RN, BSN    832-355-9408   
Principal Investigator: Willerson T. James, MD         
United States, Utah
University of Utah Health Care Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Matthew J Brobeck, BS    801-585-6743   
Contact: Patty Meldrum, BSN    801.581.4121   
Principal Investigator: Amit Patel, MD         
Sponsors and Collaborators
Cytori Therapeutics
Principal Investigator: Emerson Perin, MD, PhD Texas Heart Institute, Houston, TX
Principal Investigator: Timothy Henry, MD Minneapolis Heart Institute Foundation, Minneapolis, MN
  More Information

No publications provided

Responsible Party: Cytori Therapeutics Identifier: NCT01556022     History of Changes
Other Study ID Numbers: The ATHENA Trial
Study First Received: March 14, 2012
Last Updated: January 30, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cytori Therapeutics:
Chronic myocardial ischemia
Adipose-derived regenerative cells

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Pathologic Processes
Vascular Diseases processed this record on October 23, 2014